Standard BioTools

LAB · NASDAQ

$0.6373−$0.006 (−0.93%)TodayMarket closed ·
Prev close $0.6433

Latest news

  • Press releasePRNewswire

    Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Proxy and Looming Shareholder Merger Vote --VRME, VAL, LAB and FTHM

  • Press releasePRNewswire

    INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LAB

  • Press releasePRNewswire

    Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--NCSM, PSBQ, LAB, and RLYB

  • Press releaseGlobe Newswire

    Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction

  • Press releasePRNewswire

    Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders

  • NewsAvi Kapoor

    Crude Oil Gains Over 1%; Motorcar Parts Of America Shares Surge After Q4 Earnings

  • News

    Standard BioTools To Merge With Treeline Bioscience In All-Stock Transaction That Values LAB At Estimated $460M; Combined Company Expected To Operate As Treeline Biosciences And Trade On Nasdaq Under Symbol 'TRLN'

  • Press releaseGlobe Newswire

    Standard BioTools and Treeline Biosciences Announce Merger Agreement

  • News

    Earnings Scheduled For May 5, 2026

  • News

    Standard BioTools Q4 Earnings Report: What Investors Need to Know

  • News

    Earnings Scheduled For February 24, 2026

  • News

    Preview: Standard BioTools's Earnings

  • NewsAvi Kapoor

    Neogen Posts Strong Q2 Earnings, Joins Astronics, Lockheed Martin, Constellation Brands And Other Big Stocks Moving Higher On Thursday

  • NewsAvi Kapoor

    Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

  • Press releaseBusiness Wire

    Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

  • NewsAvi Kapoor

    Why Gorilla Technology Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

  • Press releasePRNewswire

    Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

  • News

    Earnings Scheduled For November 4, 2025

  • Press releasePRNewswire

    Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

  • Press releaseGlobe Newswire

    Standard BioTools Reports Second Quarter 2025 Financial Results

  • News

    Earnings Scheduled For August 11, 2025

  • NewsVandana Singh

    SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push

  • Press releasePRNewswire

    Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

  • News

    Standard BioTools Sells SomaLogic To Illumina For Up To $425M, Plus Future Royalties

  • Press releaseGlobe Newswire

    Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

  • NewsAvi Kapoor

    Standard BioTools And 3 Other Stocks Under $3 Executives Are Buying

  • NewsAvi Kapoor

    $1.7M Bet On Standard BioTools? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying

  • NewsAvi Kapoor

    MercadoLibre Posts Upbeat Results, Joins Integral Ad Science, Willdan Group, Fresh Del Monte Produce And Other Big Stocks Moving Higher On Friday

  • NewsAvi Kapoor

    Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

  • NewsAvi Kapoor

    Western Digital, Udemy, Teladoc Health And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.